Comparative cutoff points for adenosine monophosphate and methacholine challenge testing
Current use of the PC 20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction. To evaluate the efficacy and safety of lower cutoff points for adenosine...
Gespeichert in:
Veröffentlicht in: | Annals of allergy, asthma, & immunology asthma, & immunology, 2004-10, Vol.93 (4), p.365-372 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 372 |
---|---|
container_issue | 4 |
container_start_page | 365 |
container_title | Annals of allergy, asthma, & immunology |
container_volume | 93 |
creator | Fardon, Tom C. Fardon, Emma J. Hodge, Melissa R. Lipworth, Brian J. |
description | Current use of the PC
20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction.
To evaluate the efficacy and safety of lower cutoff points for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenge tools to monitor response to treatment in chronic asthma.
We retrospectively examined data from 5 previously published studies (2 using AMP, 2 using MCH, and 1 with MCH and AMP arms) and recalculated 10% and 15% cutoff points for AMP and MCH. Data were analyzed for correlation of single results and doubling dose shifts after anti-inflammatory treatment intervention.
A total of 175 individual MCH challenges and 152 AMP challenges were evaluated. Evaluating the doubling dose shift produced by the addition of anti-inflammatory treatment (inhaled corticosteroids or montelukast) produced the following Pearson correlation coefficients: MCH PD
20 (provocation dose that causes a decrease in forced expiratory volume in 1 second of 20%) vs PD
15, 0.80; MCH PD
20 vs PD
10, 0.65; AMP PC
20 vs PC
15, 0.96; and AMP PC
20 vs PC
10, 0.84 (
P < .001 for all). Subgroup analysis of AMP for before and after inhaled corticosteroids only (n = 41) shows AMP PC
20 vs PC
15 of 0.92 and AMP PC
20 vs PC
10 of 0.84 (
P < .001 for both).
The 10% and 15% cutoff points strongly predict the 20% cutoff value for AMP and MCH, as do the doubling dose shifts after anti-inflammatory treatment. The lower thresholds are suitable for monitoring response to therapy, and they expose patients to significantly less provocation agent. |
doi_str_mv | 10.1016/S1081-1206(10)61396-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67033869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1081120610613968</els_id><sourcerecordid>67033869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-b80d5c7f06960a8baad65347f6c718a924ff1128d3843b568b068bb3f6db88633</originalsourceid><addsrcrecordid>eNqFkE2L1TAUhoMozjj6E5QiKLqo5jRtmq5ELn7BgAsV3IU0OZlmaJOapAP-e9O5VwbcuAgJyXNO3vMQ8hToG6DA334DKqCGhvJXQF9zYAOvxT1yDh1r67Zl_H45_0XOyKOUrimlIDh7SM6g6xpgPTsnPw9hWVVU2d1gpbccrK3W4HxOlQ2xUgZ9SM5jtQQf1imkdVIZK-VNtWCelJ7CvD_rSc0z-iusMqbs_NVj8sCqOeGT035Bfnz88P3wub78-unL4f1lrVsQuR4FNZ3uLeUDp0qMShleJugt1z0INTSttQCNMEy0bOy4GGlZI7PcjKIMwy7Iy2PfNYZfW_lbLi5pnGflMWxJ8p4yJvhQwOf_gNdhi75kkw1teiGooAXqjpCOIaWIVq7RLSr-lkDl7l3eepe71P3q1rsUpe7Zqfk2Lmjuqk6iC_DiBKik1Wyj8tqlO443MDTdnvLdkcPi7MZhlEk79BqNi6izNMH9J8ofRf6fNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>202788080</pqid></control><display><type>article</type><title>Comparative cutoff points for adenosine monophosphate and methacholine challenge testing</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fardon, Tom C. ; Fardon, Emma J. ; Hodge, Melissa R. ; Lipworth, Brian J.</creator><creatorcontrib>Fardon, Tom C. ; Fardon, Emma J. ; Hodge, Melissa R. ; Lipworth, Brian J.</creatorcontrib><description>Current use of the PC
20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction.
To evaluate the efficacy and safety of lower cutoff points for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenge tools to monitor response to treatment in chronic asthma.
We retrospectively examined data from 5 previously published studies (2 using AMP, 2 using MCH, and 1 with MCH and AMP arms) and recalculated 10% and 15% cutoff points for AMP and MCH. Data were analyzed for correlation of single results and doubling dose shifts after anti-inflammatory treatment intervention.
A total of 175 individual MCH challenges and 152 AMP challenges were evaluated. Evaluating the doubling dose shift produced by the addition of anti-inflammatory treatment (inhaled corticosteroids or montelukast) produced the following Pearson correlation coefficients: MCH PD
20 (provocation dose that causes a decrease in forced expiratory volume in 1 second of 20%) vs PD
15, 0.80; MCH PD
20 vs PD
10, 0.65; AMP PC
20 vs PC
15, 0.96; and AMP PC
20 vs PC
10, 0.84 (
P < .001 for all). Subgroup analysis of AMP for before and after inhaled corticosteroids only (n = 41) shows AMP PC
20 vs PC
15 of 0.92 and AMP PC
20 vs PC
10 of 0.84 (
P < .001 for both).
The 10% and 15% cutoff points strongly predict the 20% cutoff value for AMP and MCH, as do the doubling dose shifts after anti-inflammatory treatment. The lower thresholds are suitable for monitoring response to therapy, and they expose patients to significantly less provocation agent.</description><identifier>ISSN: 1081-1206</identifier><identifier>EISSN: 1534-4436</identifier><identifier>DOI: 10.1016/S1081-1206(10)61396-8</identifier><identifier>PMID: 15521373</identifier><identifier>CODEN: ANAEA3</identifier><language>eng</language><publisher>McLean, VA: Elsevier Inc</publisher><subject><![CDATA[Acetates - administration & dosage ; Acetates - therapeutic use ; Adenosine Monophosphate - administration & dosage ; Administration, Inhalation ; Adrenal Cortex Hormones - administration & dosage ; Adrenal Cortex Hormones - therapeutic use ; Anti-Asthmatic Agents - administration & dosage ; Anti-Asthmatic Agents - therapeutic use ; Asthma - drug therapy ; Biological and medical sciences ; Bronchial Hyperreactivity - drug therapy ; Bronchial Provocation Tests - methods ; Bronchial Provocation Tests - standards ; Bronchoconstrictor Agents - administration & dosage ; Forced Expiratory Volume ; Humans ; Immunopathology ; Medical sciences ; Methacholine Chloride - administration & dosage ; Quinolines - administration & dosage ; Quinolines - therapeutic use ; Retrospective Studies]]></subject><ispartof>Annals of allergy, asthma, & immunology, 2004-10, Vol.93 (4), p.365-372</ispartof><rights>2004 American College of Allergy, Asthma & Immunology</rights><rights>2004 INIST-CNRS</rights><rights>Copyright American College of Allergy and Immunology Oct 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-b80d5c7f06960a8baad65347f6c718a924ff1128d3843b568b068bb3f6db88633</citedby><cites>FETCH-LOGICAL-c418t-b80d5c7f06960a8baad65347f6c718a924ff1128d3843b568b068bb3f6db88633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1081-1206(10)61396-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16219259$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15521373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fardon, Tom C.</creatorcontrib><creatorcontrib>Fardon, Emma J.</creatorcontrib><creatorcontrib>Hodge, Melissa R.</creatorcontrib><creatorcontrib>Lipworth, Brian J.</creatorcontrib><title>Comparative cutoff points for adenosine monophosphate and methacholine challenge testing</title><title>Annals of allergy, asthma, & immunology</title><addtitle>Ann Allergy Asthma Immunol</addtitle><description>Current use of the PC
20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction.
To evaluate the efficacy and safety of lower cutoff points for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenge tools to monitor response to treatment in chronic asthma.
We retrospectively examined data from 5 previously published studies (2 using AMP, 2 using MCH, and 1 with MCH and AMP arms) and recalculated 10% and 15% cutoff points for AMP and MCH. Data were analyzed for correlation of single results and doubling dose shifts after anti-inflammatory treatment intervention.
A total of 175 individual MCH challenges and 152 AMP challenges were evaluated. Evaluating the doubling dose shift produced by the addition of anti-inflammatory treatment (inhaled corticosteroids or montelukast) produced the following Pearson correlation coefficients: MCH PD
20 (provocation dose that causes a decrease in forced expiratory volume in 1 second of 20%) vs PD
15, 0.80; MCH PD
20 vs PD
10, 0.65; AMP PC
20 vs PC
15, 0.96; and AMP PC
20 vs PC
10, 0.84 (
P < .001 for all). Subgroup analysis of AMP for before and after inhaled corticosteroids only (n = 41) shows AMP PC
20 vs PC
15 of 0.92 and AMP PC
20 vs PC
10 of 0.84 (
P < .001 for both).
The 10% and 15% cutoff points strongly predict the 20% cutoff value for AMP and MCH, as do the doubling dose shifts after anti-inflammatory treatment. The lower thresholds are suitable for monitoring response to therapy, and they expose patients to significantly less provocation agent.</description><subject>Acetates - administration & dosage</subject><subject>Acetates - therapeutic use</subject><subject>Adenosine Monophosphate - administration & dosage</subject><subject>Administration, Inhalation</subject><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Anti-Asthmatic Agents - administration & dosage</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Bronchial Hyperreactivity - drug therapy</subject><subject>Bronchial Provocation Tests - methods</subject><subject>Bronchial Provocation Tests - standards</subject><subject>Bronchoconstrictor Agents - administration & dosage</subject><subject>Forced Expiratory Volume</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Medical sciences</subject><subject>Methacholine Chloride - administration & dosage</subject><subject>Quinolines - administration & dosage</subject><subject>Quinolines - therapeutic use</subject><subject>Retrospective Studies</subject><issn>1081-1206</issn><issn>1534-4436</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE2L1TAUhoMozjj6E5QiKLqo5jRtmq5ELn7BgAsV3IU0OZlmaJOapAP-e9O5VwbcuAgJyXNO3vMQ8hToG6DA334DKqCGhvJXQF9zYAOvxT1yDh1r67Zl_H45_0XOyKOUrimlIDh7SM6g6xpgPTsnPw9hWVVU2d1gpbccrK3W4HxOlQ2xUgZ9SM5jtQQf1imkdVIZK-VNtWCelJ7CvD_rSc0z-iusMqbs_NVj8sCqOeGT035Bfnz88P3wub78-unL4f1lrVsQuR4FNZ3uLeUDp0qMShleJugt1z0INTSttQCNMEy0bOy4GGlZI7PcjKIMwy7Iy2PfNYZfW_lbLi5pnGflMWxJ8p4yJvhQwOf_gNdhi75kkw1teiGooAXqjpCOIaWIVq7RLSr-lkDl7l3eepe71P3q1rsUpe7Zqfk2Lmjuqk6iC_DiBKik1Wyj8tqlO443MDTdnvLdkcPi7MZhlEk79BqNi6izNMH9J8ofRf6fNA</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Fardon, Tom C.</creator><creator>Fardon, Emma J.</creator><creator>Hodge, Melissa R.</creator><creator>Lipworth, Brian J.</creator><general>Elsevier Inc</general><general>American College of Allergy, Asthma, & Immunology</general><general>American College of Allergy and Immunology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20041001</creationdate><title>Comparative cutoff points for adenosine monophosphate and methacholine challenge testing</title><author>Fardon, Tom C. ; Fardon, Emma J. ; Hodge, Melissa R. ; Lipworth, Brian J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-b80d5c7f06960a8baad65347f6c718a924ff1128d3843b568b068bb3f6db88633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acetates - administration & dosage</topic><topic>Acetates - therapeutic use</topic><topic>Adenosine Monophosphate - administration & dosage</topic><topic>Administration, Inhalation</topic><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Anti-Asthmatic Agents - administration & dosage</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Bronchial Hyperreactivity - drug therapy</topic><topic>Bronchial Provocation Tests - methods</topic><topic>Bronchial Provocation Tests - standards</topic><topic>Bronchoconstrictor Agents - administration & dosage</topic><topic>Forced Expiratory Volume</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Medical sciences</topic><topic>Methacholine Chloride - administration & dosage</topic><topic>Quinolines - administration & dosage</topic><topic>Quinolines - therapeutic use</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fardon, Tom C.</creatorcontrib><creatorcontrib>Fardon, Emma J.</creatorcontrib><creatorcontrib>Hodge, Melissa R.</creatorcontrib><creatorcontrib>Lipworth, Brian J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of allergy, asthma, & immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fardon, Tom C.</au><au>Fardon, Emma J.</au><au>Hodge, Melissa R.</au><au>Lipworth, Brian J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative cutoff points for adenosine monophosphate and methacholine challenge testing</atitle><jtitle>Annals of allergy, asthma, & immunology</jtitle><addtitle>Ann Allergy Asthma Immunol</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>93</volume><issue>4</issue><spage>365</spage><epage>372</epage><pages>365-372</pages><issn>1081-1206</issn><eissn>1534-4436</eissn><coden>ANAEA3</coden><abstract>Current use of the PC
20 (provocation concentration that causes a decrease in forced expiratory volume in 1 second of 20%) cutoff point for bronchial challenge precludes its use in patients with more severe airflow obstruction.
To evaluate the efficacy and safety of lower cutoff points for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenge tools to monitor response to treatment in chronic asthma.
We retrospectively examined data from 5 previously published studies (2 using AMP, 2 using MCH, and 1 with MCH and AMP arms) and recalculated 10% and 15% cutoff points for AMP and MCH. Data were analyzed for correlation of single results and doubling dose shifts after anti-inflammatory treatment intervention.
A total of 175 individual MCH challenges and 152 AMP challenges were evaluated. Evaluating the doubling dose shift produced by the addition of anti-inflammatory treatment (inhaled corticosteroids or montelukast) produced the following Pearson correlation coefficients: MCH PD
20 (provocation dose that causes a decrease in forced expiratory volume in 1 second of 20%) vs PD
15, 0.80; MCH PD
20 vs PD
10, 0.65; AMP PC
20 vs PC
15, 0.96; and AMP PC
20 vs PC
10, 0.84 (
P < .001 for all). Subgroup analysis of AMP for before and after inhaled corticosteroids only (n = 41) shows AMP PC
20 vs PC
15 of 0.92 and AMP PC
20 vs PC
10 of 0.84 (
P < .001 for both).
The 10% and 15% cutoff points strongly predict the 20% cutoff value for AMP and MCH, as do the doubling dose shifts after anti-inflammatory treatment. The lower thresholds are suitable for monitoring response to therapy, and they expose patients to significantly less provocation agent.</abstract><cop>McLean, VA</cop><pub>Elsevier Inc</pub><pmid>15521373</pmid><doi>10.1016/S1081-1206(10)61396-8</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1081-1206 |
ispartof | Annals of allergy, asthma, & immunology, 2004-10, Vol.93 (4), p.365-372 |
issn | 1081-1206 1534-4436 |
language | eng |
recordid | cdi_proquest_miscellaneous_67033869 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Acetates - administration & dosage Acetates - therapeutic use Adenosine Monophosphate - administration & dosage Administration, Inhalation Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - therapeutic use Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - therapeutic use Asthma - drug therapy Biological and medical sciences Bronchial Hyperreactivity - drug therapy Bronchial Provocation Tests - methods Bronchial Provocation Tests - standards Bronchoconstrictor Agents - administration & dosage Forced Expiratory Volume Humans Immunopathology Medical sciences Methacholine Chloride - administration & dosage Quinolines - administration & dosage Quinolines - therapeutic use Retrospective Studies |
title | Comparative cutoff points for adenosine monophosphate and methacholine challenge testing |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T19%3A53%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20cutoff%20points%20for%20adenosine%20monophosphate%20and%20methacholine%20challenge%20testing&rft.jtitle=Annals%20of%20allergy,%20asthma,%20&%20immunology&rft.au=Fardon,%20Tom%20C.&rft.date=2004-10-01&rft.volume=93&rft.issue=4&rft.spage=365&rft.epage=372&rft.pages=365-372&rft.issn=1081-1206&rft.eissn=1534-4436&rft.coden=ANAEA3&rft_id=info:doi/10.1016/S1081-1206(10)61396-8&rft_dat=%3Cproquest_cross%3E67033869%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=202788080&rft_id=info:pmid/15521373&rft_els_id=S1081120610613968&rfr_iscdi=true |